Sugi Predict

Sugi Predict / Compounds / SCHEMBL1531592

SCHEMBL1531592

SCHEMBL1531592

CC(C)(C)OC(=O)N[C@H](CO)Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 4/20 0.62
▸ CTSK P43235 3/20 0.62
▸ ATM Q13315 1/20 0.62
▸ APP P05067 4/20 0.54
▸ CTSB P07858 2/20 0.53
▸ CTSL P07711 1/20 0.53
▸ ACE P12821 4/20 0.52
▸ MME P08473 4/20 0.52
▸ BCL2 P10415 1/20 0.52
▸ MAPK1 P28482 2/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ PPARA Q07869 2/20 0.49
▸ PPARG P37231 1/20 0.49
▸ ROCK2 O75116 1/20 0.49
▸ RPS6KA5 O75582 1/20 0.49
▸ RPS6KA4 O75676 1/20 0.49
▸ PRKACA P17612 1/20 0.49
▸ GSK3A P49840 1/20 0.49
▸ GSK3B P49841 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1531589 1.00 CTSS (0.62) CTSSCTSKATMAPPCTSB
SCHEMBL15521493 1.00 CTSS (0.62) CTSSCTSKATMAPPCTSB
SCHEMBL1529562 0.92 ATM (0.71) CTSSCTSKATMAPPCTSB
SCHEMBL271855 0.92 ATM (0.71) CTSSCTSKATMAPPCTSB
SCHEMBL257912 0.92 ATM (0.71) CTSSCTSKATMAPPCTSB
SCHEMBL16945133 0.90 CTSS (0.62) CTSSCTSKATMAPPCTSB
SCHEMBL825492 0.88 CTSS (0.61) CTSSCTSKATMAPPCTSB
SCHEMBL3699140 0.88 CTSS (0.61) CTSSCTSKATMAPPCTSB
SCHEMBL26772970 0.88 CTSS (0.61) CTSSCTSKATMAPPCTSB
SCHEMBL26772969 0.88 CTSS (0.61) CTSSCTSKATMAPPCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353853-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-11-20 — — US disclosed
CN-119630645-A Flavivirus inhibitors IRBM股份公司 2025-03-14 — — CN disclosed
EP-4282862-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-29 — — EP disclosed
US-10774036-B2 Process for early sacubitril intermediates NOVARTIS AG (CH) 2020-09-15 — — US disclosed
US-10183909-B2 Process for preparation of N-Boc biphenyl alaninol CHIRAL QUEST (SUZHOU) CO., LTD. (CN) 2019-01-22 — — US disclosed
WO-2017059759-A1 PROCESS FOR PREPARATION OF N-BOC BIPHENYL ALANINOL CHIRAL QUEST (SUZHOU) CO., LTD. (CN) 2017-04-13 — — WO disclosed
US-8980833-B2 Tubulysine derivatives R&D-BIOPHARMACEUTICALS GMBH (DE) 2015-03-17 — — US disclosed
EP-2292639-B1 Tubulisine derivatives as anticancer drugs KEMOTECH S R L (IT) 2014-09-03 — — EP disclosed
EP-2292639-B1 Tubulisine derivatives as anticancer drugs KEMOTECH S R L (IT) 2014-09-03 — — EP disclosed
US-8772507-B2 Imidazole-benzamide anti-cancer agents CYTOKINETICS, INC. (US) 2014-07-08 — — US disclosed
US-20070197481-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-08-23 — — US disclosed
US-20070149516-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-28 — — US disclosed
US-20070149516-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-28 — — US disclosed
EP-0660840-B1 PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES CIBA GEIGY AG (CH) 1997-05-07 — — EP disclosed
WO-1996026729-A1 PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES AS ECE INHIBITORS CIBA-GEIGY AG (CH) 1996-09-06 — — WO disclosed
US-5550119-A ENDOTHELIN-CONVERTING ENZYM INHIBITORS CIBA-GEIGY CORPORATION (US) 1996-08-27 — — US disclosed
EP-0660840-A1 PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES. CIBA GEIGY AG (CH) 1995-07-05 — — EP disclosed
WO-1994005677-A1 PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES CIBA-GEIGY AG (CH) 1994-03-17 — — WO disclosed
US-5273990-A 5-Phosphonomethyleneamino aryl-substitued alkylene-1H-tetazoles CIBA-GEIGY CORPORATION (US) 1993-12-28 — — US disclosed
US-5250522-A Neutral endopeptidase inhibitors; cardiovascular disorders CIBA-GEIGY CORPORATION (US) 1993-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774036-B2 Process for early sacubitril intermediates MME, ACE, DNPEP CTSS 605/4885CTSK 643/4885ATM 4676/4885
US-10183909-B2 Process for preparation of N-Boc biphenyl alaninol RABL6, PF4, SPIN4 CTSS 1883/4885CTSK 3536/4885ATM 956/4885
US-20250353853-A1 FLAVIVIRUS INHIBITORS SPINT2, EIF2AK2, DDX5 CTSS 284/4885CTSK 714/4885ATM 4645/4885
US-20070197481-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 CTSS 1766/4885CTSK 1842/4885ATM 1110/4885
US-20070149516-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 CTSS 1766/4885CTSK 1842/4885ATM 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.